Biolab groups operations under the Biolab & Co. brand to strengthen business and accelerate global growth strategy
The launch connects the different business units, strengthens institutional performance and reinforces the structure to accelerate international expansion
Driven by internationalization and a strategy to unify its brands, Biolab announces the launch of Biolab & Co., The brand now houses the company's entire ecosystem under the “house of brands” model. The initiative strengthens the corporate architecture, increasing clarity in communication with different audiences - from the medical profession and patients to the veterinary sector, pet owners and business partners.
Currently, the brand has six business units: Biolab Farmacêutica, the 5th largest industry in medical prescriptions and a leader in cardiology; Biolab Genéricos; Avert Biolab Saúde Animal, a reference in pet care; Biolab Genéricos; Avert Saúde Humana, which operates in the similar products market; Pet Nutrition, with a presence in healthy pet snacks; and Exzell Pharma (Canada).
Each brand maintains its strength and specialty, and the integration shows that they are all part of the same group that delivers trust, innovation and care.
According to CEO Fabio Amorosino, the creation of the Biolab & Co. marks a turning point in the company's trajectory. “The brand reflects the maturity of our group and consolidates a strategy that has been built up over the last few years. In Brazil, we have strengthened our competitiveness in established markets and created structured space to expand into new fronts. While on the international stage, a single corporate identity positions us more clearly, facilitates entry into new countries and accelerates opportunities for sustainable growth and strategic partnerships,” adds Fabio.
Visual identity
About to celebrate three decades of history, the group Biolab & Co. announces a new visual identity that synthesizes solidity and modernity. Developed by the agency AR Propaganda, The project redefines the brand's positioning, reflecting the breadth of a group that is constantly expanding and modernizing.
The point is the adoption of navy blue as the master color. The choice is not just aesthetic; the tone acts as a guiding thread of trust that moves fluidly between the rigor of the B2B market and proximity to the end consumer. More than just a color, navy blue projects the integration of all the business units under a single institutional signature.
Humanization also plays a leading role: by featuring real people and pets in its communication, the brand is reaffirming its commitment to diversity and its "multi-species" culture. The move reflects the essence of a global company that values plurality and real connection at all its points of contact.
In charge of communication at Biolab & Co, Tati Marques, daughter of founding partner Cleiton de Castro Marques, explains that this new moment shapes the continuity of a history of achievements. “Today we have a robust group, with different areas of activity. A Biolab & Co. will integrate these fronts, reinforce our institutional positioning and show the market the collective strength of this group of businesses. We want to show that, regardless of the area in which they operate, they are all part of the same business that delivers trust, innovation and care”.
The tagline remains “Viva la Evolución!” (Long Live Evolution!), reinforcing the company's position of continuous investment in research, innovation and scientific development.
Strategy strengthens expansion and internationalization
Biolab closed 2025 with a turnover of R$ 3.2 billion. The new identity also reflects the demands of the moment in terms of expanding the organization, whose goal is to reach R$ 5 billion by 2027. This strength is supported by a robust structure of 1,800 sales force professionals, who make 320,000 medical visits every month, ensuring capillarity and proximity to health professionals.
The portfolio has more than 500 products and exports to the main countries in Latin America and the Middle East, with access to Central American countries projected for 2026; in addition to being backed by strong investment in research and development and 50 international partnerships.
The group operates three manufacturing units in the state of São Paulo, as well as two Research, Development and Innovation (RD&I) centers. Production capacity is also expanding, with the new industrial complex in Pouso Alegre (MG), which covers 100,000 m² and has the potential to produce 400 million units of medicines a year.
In addition to the national operation Biolab & Co. is stepping up its internationalization strategy, expanding its operations in South and Central America, Canada and Saudi Arabia, among other important markets. In Canada, it even has its own RD&I center - the only one outside the country owned by a Brazilian pharmaceutical company - which reinforces the group's global innovation strategy, in addition to Exzell Pharma, acquired in 2022.
History and family succession
Founded by brothers Cleiton and Paulo de Castro Marques, together with pharmacist Dante Alario Júnior, Biolab was born with the aim of developing therapeutic solutions based on science, innovation and proximity to the medical profession. The family's connection with the pharmaceutical sector began much earlier, with patriarch João Marques, who began his career as a medical salesman and later became a laboratory owner.
Tati Marques highlights the relevance of the Biolab & Co group brand for the future of the organization. “Uniting tradition and innovation means respecting the history built by the founders, while making room for contemporary languages and new technologies that reflect who we are today.”
This move is also connected to the organization's succession process. Alongside Tati, her sister, Manuela Marques, Supply Chain Director, and her cousin, Paulo W. Marques, Operations Director - son of co-founder Paulo de Castro Marques - are gaining responsibilities in the process to lead the future of the business, sharing important functions of the group's operation.
This process has intensified with the improvement of corporate governance, which has an advisory board made up of the founding partners, the former president of Banco do Brasil, Cássio Casseb Lima; the former CTO of Itaú Unibanco, João Bezerra Leite; the CEO of 3M Brasil, Paulo Gandolfi; and the executive Adriano Treve, a newcomer who brings his extensive experience in senior leadership positions in large healthcare companies.